Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Derazantinib 25 mg QOD - 200 mg QD - Low Dose Group	29
Overall Study	STARTED	Derazantinib 250 mg QOD - 325 mg QD -Middle Dose Group	13
Overall Study	STARTED	Derazantinib 400 mg QOD - 425 mg QD - High Dose Group	19
Overall Study	STARTED	Derazantinib 300 mg QD - Expanded Cohort Group	58
Overall Study	COMPLETED	Derazantinib 25 mg QOD - 200 mg QD - Low Dose Group	0
Overall Study	COMPLETED	Derazantinib 250 mg QOD - 325 mg QD -Middle Dose Group	0
Overall Study	COMPLETED	Derazantinib 400 mg QOD - 425 mg QD - High Dose Group	0
Overall Study	COMPLETED	Derazantinib 300 mg QD - Expanded Cohort Group	0
Overall Study	NOT COMPLETED	Derazantinib 25 mg QOD - 200 mg QD - Low Dose Group	29
Overall Study	NOT COMPLETED	Derazantinib 250 mg QOD - 325 mg QD -Middle Dose Group	13
Overall Study	NOT COMPLETED	Derazantinib 400 mg QOD - 425 mg QD - High Dose Group	19
Overall Study	NOT COMPLETED	Derazantinib 300 mg QD - Expanded Cohort Group	58

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01752920/flow